Interferon regulatory factor 1 (IRF1)
IRF1, or interferon regulatory factor 1, is a transcription factor that plays a central role in immune and inflammatory gene regulation.
IRF1, or interferon regulatory factor 1, is a transcription factor that plays a central role in immune and inflammatory gene regulation. It is best known for mediating interferon-responsive transcriptional programs and for integrating signals from pathways such as JAK2/signal transducer and activator of transcription 3 (STAT3) signaling, MAPK signaling, and Mechanistic target of rapamycin (mTOR)-related networks. In cancer and inflammatory biology, IRF1 is often studied as a context-dependent regulator of cell-state transitions, cytokine responses, and immune checkpoint-related pathways.
Recent studies have highlighted IRF1 as a biologically important node linking pathway inhibition to downstream transcriptional reprogramming. Depending on the cellular context, IRF1 can promote proinflammatory responses, regulate genes involved in immune evasion or antitumor immunity, and participate in transcriptional complexes that influence tumor progression and therapy response. Its relevance spans endothelial inflammation, cholangiocarcinoma, non-small cell lung cancer, and KRAS-MAPK-driven adaptive signaling.
Where the papers sit
9 papers from the last 6 months study Interferon regulatory factor 1 (IRF1) directly · updated from PubMed 3 Oct 2026
Study type 0 clinical trials · 1 observational · 7 preclinical · 1 unclassified
Themes no clear themes
Those 9 do not share a common subject.
-
IRF1 appears across immune, inflammatory and tissue-repair contexts rather than one shared disease program. In cancer, it is linked to NLRC5–MHC-I antigen presentation, FGL1 degradation, interferon-driven state transitions and checkpoint resistance. Other studies connect it to HOXA2-dependent bone healing, TRIM32/TRAF6-regulated pyroptosis, mTOR-inhibited endothelial inflammation and cuproptosis. The set offers no coherent therapeutic direction, spanning vaccines, anti-PD-1, sinomenine and predictive modeling.
Papers
The 9 papers from the last 6 months that study Interferon regulatory factor 1 (IRF1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (9)
- CO2-releasing hydrogels promote bone healing by activating transcription factor IRF1 to regulate HOXA2. Journal of molecular histology · 13 Aug 2026 PMID 42587203
- A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
- Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma. Journal for immunotherapy of cancer · 7 Jul 2026 PMID 42413983
- Sinomenine Regulates the TRIM32/IRF1/TRAF6 Axis to Inhibit Pyroptosis in Atopic Dermatitis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 3 Jul 2026 PMID 42394466
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- IRF-1 Links Cytoskeletal Contraction With Inflammatory Response in mTOR-Inhibited Endothelial Cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 11 Jun 2026 PMID 42273992
- A Single-Cell Guided Machine Learning Model Predicts Response to Immune Checkpoint Inhibitors in Gastric Cancer. Journal of chemical information and modeling · 11 Jun 2026 PMID 42273856
- Targeting IRF1-TRIM21 axis enhances anti-tumor immunity by promoting ubiquitin-mediated degradation of FGL1 in non-small cell lung cancer. Communications biology · 22 Apr 2026 PMID 42020516
- Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities. Cancer research · 20 Apr 2026 PMID 42008116
By study type
Observational studies and case reports (1)
- Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma. Journal for immunotherapy of cancer · 7 Jul 2026 PMID 42413983
Preclinical: animal, cell and lab studies (7)
- CO2-releasing hydrogels promote bone healing by activating transcription factor IRF1 to regulate HOXA2. Journal of molecular histology · 13 Aug 2026 PMID 42587203
- A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
- Sinomenine Regulates the TRIM32/IRF1/TRAF6 Axis to Inhibit Pyroptosis in Atopic Dermatitis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 3 Jul 2026 PMID 42394466
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- IRF-1 Links Cytoskeletal Contraction With Inflammatory Response in mTOR-Inhibited Endothelial Cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 11 Jun 2026 PMID 42273992
- A Single-Cell Guided Machine Learning Model Predicts Response to Immune Checkpoint Inhibitors in Gastric Cancer. Journal of chemical information and modeling · 11 Jun 2026 PMID 42273856
- Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities. Cancer research · 20 Apr 2026 PMID 42008116
Unclassified: not yet indexed with MeSH (1)
- Targeting IRF1-TRIM21 axis enhances anti-tumor immunity by promoting ubiquitin-mediated degradation of FGL1 in non-small cell lung cancer. Communications biology · 22 Apr 2026 PMID 42020516
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-03. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.